SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Ionis Pharmaceuticals (IONS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
4676 121 0 IONS
Emcee:  Keith Fauci Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4651Mipo Morningstar gives 60% chance of approval. Blockbuster potential. torontostbob zagorin-5/15/2011
4650Isis Pharmaceuticals' and GSK's Innovative Collaboration Voted Breakthrobob zagorin-5/10/2011
4649Article from Family Practice News: NEW ORLEANS – In patients with hypercholestebob zagorin-5/7/2011
4648thanks.. mipo filing info from cc.. from the transcript "...Most significbob zagorin-5/6/2011
4647In case you wanted to know how ISIS accounts for its stake in Regulus, here’s thDewDiligence_on_SI-5/6/2011
4646Isis Reports Financial Results and Highlights for First Quarter 2011 -- Conferenbob zagorin-5/5/2011
4645Needham Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Pipelbob zagorin-4/14/2011
4644Data from Two Mipomersen Phase 3 Trials Presented at ACC Study in Patients withbob zagorin-4/5/2011
4643Isis Pharma Remains Neutral zacks We recently reiterated a Neutral recommendatibob zagorin-4/4/2011
4642Mipomersen Cut LDL Cholesterol Levels in Statin-Resistant Patients By: CAROLINEbob zagorin-4/4/2011
4641inflammation and cancerbob zagorin-4/4/2011
4640Regulus and reduction of plaque eon.businesswire.combob zagorin-3/30/2011
4639The list of clinical trials (and their dates) is very interesting because, despiArt Bechhoefer-3/28/2011
4638clinicaltrials.govbob zagorin-3/25/2011
4637Barclays Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); 4Q10 bob zagorin-3/1/2011
4636Piper Jaffray Maintains $10 PT, Neutral Rating On ISIS By BenzingaStaffL March 0bob zagorin-3/1/2011
4635Needham Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Stronbob zagorin-3/1/2011
4634repost from IV board.. "...Today’s Conference Call My quick notes on todaybob zagorin12/28/2011
4633Isis Reports Financial Results and Highlights for 2010 - Conference Call Webcastbob zagorin-2/28/2011
4632Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activbob zagorin-2/23/2011
4631PHARMA: Isis CEO says Genzyme, Sanofi deal good for Isis drug Crooke is confidebob zagorin-2/16/2011
4630from IV board From GENZ 4th qtr report Nothing new from either this report or tbob zagorin-2/16/2011
4629mipo listed in reuters factbox on deal under "key pipeline products" Fbob zagorin-2/16/2011
4628Sanofi to buy Genzyme for about $20 billion 1:21am EST PARIS (Reuters) - Frenchbob zagorin-2/16/2011
4627If Isis does a trial With chocolate as the control -- Because it makes us smile tuck12/9/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News